Back to Search
Start Over
Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice.
- Source :
-
Annals of neurology [Ann Neurol] 2020 Mar; Vol. 87 (3), pp. 480-485. Date of Electronic Publication: 2020 Jan 22. - Publication Year :
- 2020
-
Abstract
- Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480-485.<br /> (© 2020 American Neurological Association.)
- Subjects :
- Acetyltransferases antagonists & inhibitors
Amidohydrolases deficiency
Amidohydrolases genetics
Animals
Aspartic Acid biosynthesis
Ataxia complications
Ataxia drug therapy
Atrophy complications
Atrophy drug therapy
Canavan Disease complications
Canavan Disease pathology
Cerebellum pathology
Female
Gene Knockdown Techniques
Infusions, Intraventricular
Male
Mice
Mutation
Oligonucleotides, Antisense administration & dosage
Purkinje Cells pathology
Rotarod Performance Test
Thalamus pathology
Vacuoles drug effects
Vacuoles pathology
Aspartic Acid analogs & derivatives
Canavan Disease drug therapy
Oligonucleotides, Antisense therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1531-8249
- Volume :
- 87
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Annals of neurology
- Publication Type :
- Academic Journal
- Accession number :
- 31925837
- Full Text :
- https://doi.org/10.1002/ana.25674